Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series
<b>Background</b>: The current possible treatments of advanced medullary carcinoma (MTC) include different drugs belonging to the class of tyrosine kinase inhibitors (TKIs): vandetanib, cabozantinb, and selpercatinib. Although the effects of these TKIs have been well described in clinica...
Saved in:
Main Authors: | Marilda Mormando, Rosa Lauretta, Giulia Puliani, Marta Bianchini, Maria Elena Spoltore, Marialuisa Appetecchia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/12/12/2923 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Uncommon metastatic journey: unusual breast metastases of medullary thyroid carcinoma: a case report
by: Saadallah Fatma, et al.
Published: (2025-01-01) -
Medullary Thyroid Carcinoma in the Background of Non-neoplastic Toxic Nodular Goiter
by: Azra Rizwan, MBBS, FCPS Medicine, MSc Clinical Research, et al.
Published: (2024-11-01) -
Nephrotic Syndrome as a Complication of Systemic Calcitonin Amyloidosis From Long-Standing Metastatic Medullary Thyroid Cancer
by: Samantha M. Siskind, MD, et al.
Published: (2024-11-01) -
Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma
by: Omar Elghawy, et al.
Published: (2024-11-01) -
Distinct Impacts of Clinicopathological and Mutational Profiles on Long-Term Survival and Recurrence in Medullary Thyroid Carcinoma
by: Moon Young Oh, et al.
Published: (2024-12-01)